184 completed, 79 recruiting, 56 active not recruiting, 54 terminated. 260 Phase 2, 149 Phase 1, 36 Not applicable, 21 Phase 3, 5 Phase 4.
Follow Carcinoma, Neuroendocrine: new trials by email Literature Review of Carcinoma, Neuroendocrine trials Research Report on Carcinoma, Neuroendocrine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT - Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma | Not yet recruiting | British Columbia Cancer Agency | 60 | 2026-11-30 | 2026-10-06 | |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2026-10-27 | 2026-10-22 |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 ASTX727 + retifanlimab - Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 31 | 2026-10-01 | 2026-09-29 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid Cancer lobectomy with lymph node dissection - Medullary Thyroid Carcinoma | Not yet recruiting | Aristotle University Of Thessaloniki | 74 | 2026-09-30 | 2026-10-01 | |
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| Thyroid Health Outcomes Registry for Surgery Thyroid Diseases, Thyroid Neoplasms | Not yet recruiting | Pirogov Russian National Research Medical University | 3000 | 2026-09-01 | 2026-09-10 | |
| A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate PET/CT, 177Lu-DTPA-SC16.56 - Neuroendocrine Tumor of the Lung, Neuroendocrine Carcinoma of Lung | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2026-09-01 | 2026-08-06 |
| A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung Obrixtamig - Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Not yet recruiting | Technische Universität Dresden | 75 | 2026-09-01 | 2026-08-26 |
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer AK112, Irinotecan, Cisplatin - Neuroendocrine Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-08-01 | 2026-07-17 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| Study of SNH-118110 in Advanced Solid Tumors SNH-118110 Soft Capsules - Solid Tumors | Phase 1 | Not yet recruiting | ScinnoHub Pharmaceutical Co., Ltd. | 240 | 2026-06-26 | 2026-06-16 |
Showing 20 of 467. Sign in to see all of them.
Carcinoma, Merkel Cell (147) · Carcinoma, Medullary (141) · Melanoma (75) · Carcinoma, Non-Small-Cell Lung (69) · Neuroendocrine Tumors (64) · Small Cell Lung Carcinoma (61) · Thyroid Neoplasms (56) · Somatostatinoma (51) · Carcinoma, Renal Cell (49) · Carcinoma, Hepatocellular (48) · Neoplasms (47) · Neoplasm Metastasis (45) · Uterine Cervical Neoplasms (43) · Stomach Neoplasms (42)
Neoplasms, Glandular and Epithelial (464) · Neuroectodermal Tumors (464) · Adenocarcinoma (463) · Neoplasms by Histologic Type (463) · Neoplasms, Germ Cell and Embryonal (463) · Carcinoma (450) · Neoplasms, Nerve Tissue (433) · Neoplasms (420) · Neuroendocrine Tumors (403) · Neoplasms by Site (268) · Endocrine System Diseases (166) · Endocrine Gland Neoplasms (163) · DNA Virus Infections (150) · Infections (150)
pembrolizumab (35) · Nivolumab (30) · avelumab (24) · Cisplatin (19) · Everolimus (18) · Ipilimumab (16) · vandetanib (14) · Etoposide (12) · Magnetic Resonance Spectroscopy (12) · atezolizumab (12) · cabozantinib (12) · Bevacizumab (11) · Capecitabine (11) · Cyclophosphamide (11) · Radiotherapy (11)
National Cancer Institute (NCI) (50) · M.D. Anderson Cancer Center (19) · Memorial Sloan Kettering Cancer Center (10) · H. Lee Moffitt Cancer Center and Research Institute (8) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (7) · Genzyme, a Sanofi Company (6) · Novartis Pharmaceuticals (6) · Peking University (6) · AbbVie (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · ECOG-ACRIN Cancer Research Group (4) · Eli Lilly and Company (4) · Exelixis (4) · Fate Therapeutics (4) · Fred Hutchinson Cancer Center (4)
United States (284) · France (52) · Italy (47) · China (42) · Spain (42) · Canada (38) · Australia (35) · Germany (34) · United Kingdom (25) · Netherlands (24) · Belgium (22) · South Korea (22) · Japan (20) · Poland (17) · Denmark (15)
Jason Wu (5) · Jaydira Del Rivero, M.D. (4) · Andrew S Brohl, MD (3) · Andreas Kjaer, MD (2) · Anish Thomas, M.D. (2) · Aude Chapuis (2)
PMID 36657661, PMID 37934000, PMID 42580817, PMID 14673042, PMID 15999359, PMID 16877720, PMID 17405835, PMID 17985341, PMID 17985985, PMID 18596272, PMID 18854394, PMID 19372041, PMID 19602035, PMID 19735988, PMID 19886987, PMID 20145168, PMID 20739388, PMID 20851682, PMID 21358115, PMID 21367608, PMID 21606412, PMID 21757257, PMID 21831734, PMID 22025146, PMID 22480131, PMID 22722717, PMID 23489023, PMID 23516312, PMID 23676418, PMID 23766359, PMID 24002501, PMID 24050953, PMID 24617713, PMID 24628963, PMID 24848831, PMID 25086465, PMID 25117183, PMID 25318437, PMID 25426617, PMID 25488966, PMID 25810047, PMID 25900182, PMID 25956795, PMID 25972901, PMID 25991462, PMID 26462967, PMID 26678657, PMID 26769865, PMID 27020837, PMID 27093365
2016 (7), 2018 (7), 2023 (7), 2019 (5), N01CM62205 (5), N01CM62207 (5), P30CA015704 (5), P30CA016672 (4), U10CA180820 (4), 2014 (3), P30CA015083 (3), U10CA021115 (3), U10CA032102 (3), UM1CA186691 (3), K24CA139052 (2)